Rationalizing Effective Phase 1 Trial Design for Combination Therapies: Combining Mesothelin-Specific CAR-T (huCART-meso) Cells with Oncolytic Virus VCN-01

Time: 10:00 am
day: Focus Day Track 1

Speakers: